RNS Number : 0175D
Genedrive PLC
01 April 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA OR JAPAN.

genedrive plc

("**genedrive**" or the "**Company**")

Result of RetailBook Offer

genedrive plc (**AIM:GDR**), the point-of-care pharmacogenetic testing companyannounced on 27 March 2025 the launch of a fundraising comprising a Subscription in conjunction with a retail offer via RetailBook (the "**RetailBook Offer**", together with the Subscription, the "**Fundraising**").

The Company is pleased to announce that the RetailBook Offer successfully completed and closed at 5.00 p.m. on 31 March 2025 and that it has conditionally raised approximately £226,308.92in the RetailBook Offer through the issue of 15,087,261 new Ordinary Shares at the Issue Price of 1.5 pence per share.

Accordingly, following the close of the RetailBook Offer, the Company has conditionally raised gross proceeds of approximately £1.23 million at the Issue Price via the Fundraising requiring the issue and allotment of 81,753,927 new Ordinary Shares (the "**Fundraising Shares**").

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the Equity fundraise announcement.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for the Fundraising Shares to be admitted to trading on trading on AIM. Admission is expected to take place and dealings in the Fundraising Shares are expected to commence at 8.00 a.m. on 3 April 2025, at which time it is also expected that the Fundraising Shares will be enabled for settlement in CREST.

Immediately following Admission, the issued share capital of the Company is expected to comprise 624,895,408 Ordinary Shares. Each Ordinary Share has one voting right and no Ordinary Shares are held in treasury. From Admission, this figure may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

genedrive plc +44 (0) 161 989 0245
Gino Miele: CEO / Russ Shaw: CFO

RetailBook Limited capitalmarkets@retailbook.com
Nick Smith / Michael Ward

Peel Hunt LLP, Nominated Adviser and Broker +44 (0) 20 7418 8900
James Steel

Walbrook PR Ltd (Media & Investor Relations) +44 (0) 20 7933 8780
Anna Dunphy orgenedrive@walbrookpr.com
+44 (0) 7876 741 001

Notes:
References to times in this Announcement are to London time unless otherwise stated.The times and dates mentioned throughout this Announcement may be adjusted by the Company in which event the Company will make an appropriate announcement to a Regulatory Information Service giving details of any revised dates and the details of the new times and dates will be notified to London Stock Exchange plc (the "**London Stock Exchange**") and, where appropriate, Shareholders. Shareholders may not receive any further written communication.

IMPORTANT INFORMATION
This Announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This Announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

This Announcement and the information contained herein, is restricted and is not for publication, release or distribution, directly or indirectly, in whole or in part, in or into Australia, Canada, the Republic of South Africa, Japan or any other jurisdiction in which such publication, release or distribution would be unlawful. Further, this Announcement is for information purposes only and is not an offer of securities in any jurisdiction.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROIEAXDFDAFSEFA